Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 116, Issue 1, Pages 146-151Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s12185-022-03309-9
Keywords
Acute myelogenous leukemia; Del(5q); Decitabine; Minimally myelosuppressive regimen; Allo-hematopoietic stem cell transplantation (allo-HSCT)
Categories
Funding
- Jiangsu project [CXTDA2017014, BE2019672]
- Suzhou project [SS201809, GSWS2020039]
- National Clinical Research Center for Hematological Disorders [2020ZKPB02]
- NCI [CA21765]
- ALSAC
- St. Jude Departments of Oncology and Global Pediatric Medicine
Ask authors/readers for more resources
Cases of pediatric acute myeloid leukemia (AML) with complex karyotypes including chromosome 5 abnormalities are rare and have a very poor prognosis. This study shows that combination therapy can effectively induce remission with good tolerability and improve survival rates in this subtype of AML patients.
Cases of pediatric acute myeloid leukemia (AML) with complex karyotypes including chromosome 5 abnormalities are rare and have a very poor prognosis. Management of AML with monosomy 5/del(5q) has been inconsistent. We treated three adolescents with this AML subtype using combined low-dose cytarabine and mitoxantrone, concurrently with decitabine and G-CSF, for remission induction. Decitabine was also included in the conditioning regimen before hematopoietic cell transplantation (HCT). All three patients achieved complete remission after treatment with this combination therapy. The treatment was well tolerated, and the patients are alive and free of disease at 3.6, 3.2, and 3.0 years after HCT, respectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available